Regulatory Science and Innovation Programme for Europe (ReScIPE): A proposed model

Philip A. Hines, Richard H. Guy, Angela Brand, Anthony J. Humphreys, Marisa Papaluca-Amati

Research output: Contribution to journalArticle

Abstract

Regulatory science underpins the objective evaluation of medicinal products. It is therefore imperative that regulatory science and expertise remain at the cutting edge so that innovations of ever-increasing complexity are translated safely and swiftly into effective, high-quality therapies. We undertook a comprehensive examination of the evolution of science and technology impacting on medicinal product evaluation over the next 5–10 years and this horizon-scanning activity was complemented by extensive stakeholder interviews, resulting in a number of significant recommendations. Highlighted in particular was the need for expertise and regulatory science research to fill knowledge gaps in both more fundamental, longer-term research, with respect to technological and product-specific challenges. A model is proposed to realise these objectives in Europe, comprising a synergistic relationship between the European Medicines Agency, the European Medicines Regulatory Network and academic research centres to establish a novel regulatory science and innovation platform.

Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
DOIs
Publication statusAccepted/In press - 01-01-2019

Fingerprint

Research
Interviews
Technology
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Hines, Philip A. ; Guy, Richard H. ; Brand, Angela ; Humphreys, Anthony J. ; Papaluca-Amati, Marisa. / Regulatory Science and Innovation Programme for Europe (ReScIPE) : A proposed model. In: British Journal of Clinical Pharmacology. 2019.
@article{cda72c53c68f4519b1df62e739f71528,
title = "Regulatory Science and Innovation Programme for Europe (ReScIPE): A proposed model",
abstract = "Regulatory science underpins the objective evaluation of medicinal products. It is therefore imperative that regulatory science and expertise remain at the cutting edge so that innovations of ever-increasing complexity are translated safely and swiftly into effective, high-quality therapies. We undertook a comprehensive examination of the evolution of science and technology impacting on medicinal product evaluation over the next 5–10 years and this horizon-scanning activity was complemented by extensive stakeholder interviews, resulting in a number of significant recommendations. Highlighted in particular was the need for expertise and regulatory science research to fill knowledge gaps in both more fundamental, longer-term research, with respect to technological and product-specific challenges. A model is proposed to realise these objectives in Europe, comprising a synergistic relationship between the European Medicines Agency, the European Medicines Regulatory Network and academic research centres to establish a novel regulatory science and innovation platform.",
author = "Hines, {Philip A.} and Guy, {Richard H.} and Angela Brand and Humphreys, {Anthony J.} and Marisa Papaluca-Amati",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/bcp.14099",
language = "English",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",

}

Regulatory Science and Innovation Programme for Europe (ReScIPE) : A proposed model. / Hines, Philip A.; Guy, Richard H.; Brand, Angela; Humphreys, Anthony J.; Papaluca-Amati, Marisa.

In: British Journal of Clinical Pharmacology, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Regulatory Science and Innovation Programme for Europe (ReScIPE)

T2 - A proposed model

AU - Hines, Philip A.

AU - Guy, Richard H.

AU - Brand, Angela

AU - Humphreys, Anthony J.

AU - Papaluca-Amati, Marisa

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Regulatory science underpins the objective evaluation of medicinal products. It is therefore imperative that regulatory science and expertise remain at the cutting edge so that innovations of ever-increasing complexity are translated safely and swiftly into effective, high-quality therapies. We undertook a comprehensive examination of the evolution of science and technology impacting on medicinal product evaluation over the next 5–10 years and this horizon-scanning activity was complemented by extensive stakeholder interviews, resulting in a number of significant recommendations. Highlighted in particular was the need for expertise and regulatory science research to fill knowledge gaps in both more fundamental, longer-term research, with respect to technological and product-specific challenges. A model is proposed to realise these objectives in Europe, comprising a synergistic relationship between the European Medicines Agency, the European Medicines Regulatory Network and academic research centres to establish a novel regulatory science and innovation platform.

AB - Regulatory science underpins the objective evaluation of medicinal products. It is therefore imperative that regulatory science and expertise remain at the cutting edge so that innovations of ever-increasing complexity are translated safely and swiftly into effective, high-quality therapies. We undertook a comprehensive examination of the evolution of science and technology impacting on medicinal product evaluation over the next 5–10 years and this horizon-scanning activity was complemented by extensive stakeholder interviews, resulting in a number of significant recommendations. Highlighted in particular was the need for expertise and regulatory science research to fill knowledge gaps in both more fundamental, longer-term research, with respect to technological and product-specific challenges. A model is proposed to realise these objectives in Europe, comprising a synergistic relationship between the European Medicines Agency, the European Medicines Regulatory Network and academic research centres to establish a novel regulatory science and innovation platform.

UR - http://www.scopus.com/inward/record.url?scp=85074400030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074400030&partnerID=8YFLogxK

U2 - 10.1111/bcp.14099

DO - 10.1111/bcp.14099

M3 - Article

C2 - 31426120

AN - SCOPUS:85074400030

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

ER -